Beneficial Medicine Observing in Psychotherapy: A Significant Step in Medical Practice

P.O.Alastair and E.B.Culbert

doi:https://doi.org/10.14445/23942576/IJPBE-V4I2P101

Research Article | Open Access

Volume 4 | Issue 2 | Year 2017 | Article Id. IJPBE-V4I2P101 | DOI : https://doi.org/10.14445/23942576/IJPBE-V4I2P101

Beneficial Medicine Observing in Psychotherapy: A Significant Step in Medical Practice

P.O.Alastair and E.B.Culbert

Citation :

P.O.Alastair and E.B.Culbert, "Beneficial Medicine Observing in Psychotherapy: A Significant Step in Medical Practice," International Journal of Pharmacy and Biomedical Engineering, vol. 4, no. 2, pp. 1-4, 2017. Crossref, https://doi.org/10.14445/23942576/IJPBE-V4I2P101

Abstract

TDM in psychotherapy is an instrument to optimize the beneficial regimens in medical practice. Psychopharmacology encompasses those drugs which metabolize, and their metabolites also are active in the body. CYP-450 of antipsychotics is unique as the drugs are lipid-soluble, and the assorted class of drugs act on dissimilar types of receptors and produce changeable responses. A variety of techniques are concerned to approximate the drug levels of those drugs. HPLC is a golden typical to assay the serum drug attentiveness of these drugs. The metabolites can also be assayed along with the parent drug. TDM of these drugs, if applied at a tertiary care, individualization of the amount regime of these drugs can help the outcomes of analysis, and even drug-drug communication can exhibit the PK/PD nature of such drugs.

Keywords

TDM, PK/PD, ICD, DSM-IV, CYP, PM, CYP3A4, CYP2C19

References

[1] Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al. (1994). Opportunities for integration of pharmacokinetics.
[2] APA (2000). Diagnostic and statistical manual of mental disorders DSM‐IV‐TR. American Psychiatric Association of Washington, DC.
[3] WHO (2000). “Global Burden of Disease (GBD) 2000 estimates”. World Health Organization.
[4] Cameron OG (1999). Psychopharmacology. Psychosom Med 61(5): 585‐590.
[5] Scordo MG & Spina E (2002). “Cytochrome P450 polymorphisms and response to antipsychotic therapy”. Pharmacogenomics 3(2): 201‐218.
[6] Hardman J, Limbird L, Molinoff P, Ruddon R & Goodman Gilman A (1996). “Goodman & Gilmans The pharmacological basis of therapeutics”, 9th edition. U.S.: McGraw‐Hill Companies, Inc.
[7] Tucker GT (2000). Chiral switches. Lancet 355(9209): 1085‐ 1087.
[8] Xie HG, Kim RB, Wood AJ & Stein CM (2001). “Molecular basis of ethnic differences in drug disposition and response”. Annu Rev Pharmacol Toxicol 41: 815‐850.
[9] Spina E, Scordo MG & DʹArrigo C (2003). “Metabolic drug interactions with new psychotropic agents”. Fundam Clin Pharmacol 17(5): 517‐538.
[10] Eichelbaum M & Evert B (1996). “Influence of pharmacogenetics on drug disposition and response”. Clin Exp Pharmacol Physiol 23(10‐11): 983‐985.
[11] Bertilsson L, Dahl ML & Tybring G (1997). “Pharmacogenetics of antidepressants: clinical aspects”. Acta Psychiatr Scand Suppl 391: 14‐21.
[12] Uges DR & Schootstra R (1987). “Changed pharmacokinetics under the influence of age.” Pharm Weekbl Sci 9(2): 50‐5.
[13] Lundmark J, Reis M & Bengtsson F (2000). “Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting”. Ther Drug Monit 22(4): 446‐454.
[14] Poole Arcangelo V & Peterson AM (2006). “Pharmacotherapeutics for advanced practice:” a practical approach, 2nd edition. Philadelphia: Lippincott Williams & Wilkins.
[15] Ratanasavanh D, Beaune P, Morel F, Flinois JP, Guengerich FP & Guillouzo A (1991). “Intralobular distribution and quantitation of cytochrome P‐450 enzymes in the human liver as a function of age”. Hepatology 13(6): 1142‐1151.
[16] Beierle I, Meibohm B & Derendorf H (1999). “Gender differences in pharmacokinetics and pharmacodynamics”. Int J Clin Pharmacol Ther 37(11): 529‐547.
[17] Horsmans Y, Desager JP & Harvengt C (1992). “Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6 beta‐hydroxy cortisol in 102 healthy subjects on rifampicin”. Pharmacol Toxicol 71(4): 258-261.
[18] Kroon, LA (2007). “Drug interactions with smoking”. Am J Health Syst Pharm 64(18): 1917-1921.
[19] Carrillo JA & Benitez J (2000). “Clinically significant pharmacokinetic interactions between dietary caffeine and medications”. Clin Pharmacokinet 39(2): 127-153.
[20] Compher, CW (2004). “The impact of protein-calorie malnutrition on drugs. Handbook of Drug-Nutrient Interactions”: edited by Joseph I. Boullata and Vincent T. Armenti.
[21] Back DJ & Orme ML (1990). “Pharmacokinetic drug interactions with oral contraceptives”. Clin Pharmacokinet 18(6): 472 - 484.
[22] Goldstein LH, Elias M, Ron Avraham G, Biniaurishvili BZ, Madjar M, Kamargash I, Braunstein R, Berkovitch M & Golik A (2007). “Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards”. Br J Clin Pharmacol 64(3): 373-380.
[23] Zhou S, Chan E, Pan SQ, Huang M & Lee EJ (2004). “Pharmacokinetic interactions of drugs with St Johnʹs wort”. J Psychopharmacol 18(2): 262-276.
[24] Bjerrum L, Sogaard J, Hallas J & Kragstrup J (1998). “Polypharmacy: correlations with sex, age, and drug regimen”. A prescription database study. Eur J Clin Pharmacol 54(3): 197- 202.
[25] LeSage J (1991). “Polypharmacy in geriatric patients”. Nurs Clin North Am 26(2): 273‐90.